News

The latest from Orpyx®.

New Clinical Trial Evidence of SurroSense Rx® to be Presented at EASD 2018

Results from a randomized clinical trial ran by Manchester Metropolitan University showed the SurroSense Rx provided a 71 per cent reduction in foot ulcers over an 18-month long study. Manchester Metropolitan University will be presenting their findings at EASD 2018 (European Association for the Study of Diabetes) at the Messe Berlin Exhibition Halls in Berlin-Charlottenburg, Germany on October 2, 2018.

read more

Patent granted for Orpyx® technology in the United States

Orpyx Medical Technologies Inc. announced today that the United States Patent and Trademark Office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx® product and future products, such as SurroGait Rx, in the United States.

read more

Orpyx Launches LogR™ Gen 2 Plantar Pressure System

The Orpyx LogR™ is a clinical grade plantar pressure measurement solution, making data collection outside the lab simpler and faster without compromising data quality. With 37 pressure sensors and a 9-axis IMU sampled at a frequency of 256Hz, LogR sets a high standard for data quality. The LogR inserts are light and low profile making it comfortable to wear and perfect for real world monitoring while high durability allows them to be reusable.

read more

Orpyx awarded at Pitch@Palace Commonwealth Competition

Orpyx Medical Technologies Inc. is proud to announce that it was named as the one of the winners of the Pitch@Palace Commonwealth Competition, ranking as the first runner up. The event took place as part of the Commonwealth Summit and saw entrepreneurs from across the Commonwealth come together at St. James’s Palace on April 16, 2018.

read more

Orpyx Awarded Federal Supply Schedule (FSS) Contract

Orpyx Medical Technologies Inc. announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) contract available through Academy Medical, LLC (contract number 36F79718D0372), effective April 1, 2018. The awarding of this contract will provide all U.S. federal medical providers, including those operated by the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD) and Indian Health Services (IHS), easy access to SurroSense Rx system.

read more

Cost-effectiveness journal article published

Orpyx Medical Technologies Inc. announced today the publication of “Cost effectiveness of smart insoles in preventing ulcer recurrence for people in diabetic foot remission” in Wound Care Management. The analysis shows the cost-effectiveness of smart insoles as an adjunct to standard diabetic foot care. A pilot study completed at the University of Arizona’s Southern Arizona Limb Salvage Alliance (SALSA) provided clinical inputs for two decision tree models-one at three-months and one at eighteen-months post diabetic foot ulcer (DFU) closure, comparing current standard of care to use of the SurroSense Rx system as an adjunct to standard of care (SOC).

read more

Orpyx Technology Helps Patient with Prevention and Early Detection of Ulceration

Orpyx Medical Technologies Inc. announced today the American Society of Plastic Surgeons published “Novel Pressure-Sensing Smart Insole System Used for the Prevention of Pressure Ulceration in the Insensate Foot Case Report”. This case study explores the use of Orpyx’s SurroSense Rx® system for a patient with spina bifida, history of clubfoot, 20 operations to their right leg, and 3 years of unsuccessful wound management.

read more

World’s First Reported Case of Smart Insole Tech Managing Post-Traumatic Complications

Orpyx Medical Technologies Inc. announced today the medical journal Plastic Case Studies published “Use of the SurroSense Rx System for Sensory Substitution of the Insensate Plantar Foot Resurfaced With Latissimus Dorsi Muscle Free Flap and Skin Graft: A Retrospective Case Study”. This case study explores the use of Orpyx’s SurroSense Rx® system with a patient with the loss of protective sensation (LOPS) from a degloving injury of the right foot that was reconstructed with a latissimus dorsi free flap and skin graft.

read more

First Journal Article Published from SurroSense Rx® Pilot Study II

he Journal of Diabetes Science and Technology published “Smarter Sole Survival: Will Neuropathic Patients at High Risk for Ulceration Use a Smart Insole-Based Foot Protection System?” in the Journal of Diabetes Science and Technology today. The article is the first of several articles expected out of the second pilot study from the University of Arizona Southern Arizona Limb Salvage Alliance (SALSA) clinic under the supervision of Dr. David Armstrong.

read more

Patent granted for Orpyx technology in Australia

Orpyx Medical Technologies Inc. announced today that the Australian Patents Office has awarded Orpyx the “Peripheral Sensory and Supersensory Replacement System.” The patent covers key inventions used in both Orpyx’s SurroSense Rx (R) product and future products, such as SurroGait Rx (TM), in Australia.

read more

SurroSense Rx® Study Shows Device Effective in Encouraging Patients to Actively Offload Pressure

Dr. Bijan Najafi, Professor of Surgery and Director of Clinical Research at the Baylor College of Medicine presented the first released results of the second pilot study at University of Arizona’s Southern Arizona Limb Salvage Alliance (SALSA) at the American Diabetes Association (ADA) Scientific Sessions in New Orleans. This study, under the direction of Dr. David Armstrong, tested Orpyx’s SurroSense Rx™ with 19 participants with diabetic peripheral neuropathy and at high risk of diabetic foot ulcers over a three-month period.

read more

Orpyx’s CEO and Co-Founder awarded Governor General’s Innovation Award

Orpyx Medical Technologies Inc. (“Orpyx”) is proud to announce its CEO and Co-Founder, Dr. Breanne Everett was named one of the six national winners of the inaugural Governor General’s Innovation Award in Canada. The goal of the Governor General’s Innovation Award is to inspire Canadians to embrace innovation and to emulate innovative, entrepreneurial risk-takers who have developed new or groundbreaking ways of creating value and a meaningful impact on our quality of life.

read more

Smart Insoles: Assessing their Clinical Potential

Orpyx’s SurroSense Rx® was recently mentioned LER Magazine. Lower Extremity Review or LER Magazine fills the lower extremity information gap for practitioners in the fields of Podiatry, Physical Therapy, O&P Pedorthics, and Orthopaedics. The article discusses how athletes have been quick to embrace smart insoles and the biomechanical data generated by the devices’ embedded sensors. However, experts believe smart insoles may also have potential clinical applications for patients with foot health problems, such as diabetic neuropathy.

read more

Could New Wearable Technologies Help Replace Lost Or Impaired Plantar Pressure Proprioception?

Orpyx’s SurroGait Rx™ was recently mentioned in Volume 29 – Issue 3 – March 2016 of Podiatry Today. Podiatry Today is an award-winning, premier publication that emphasizes informative clinical features and columns as well as practice management articles. The authors Dr. Breanne Everett – Orpyx’s CEO and Co-Founder, Dr. Asmussen, and Dr. Armstrong discuss changing perspectives on neuroplasticity and the evolution of sensory substitution, and how these trends have led to wearable technology with potential benefits in this high-risk population.

read more

Patent granted for Orpyx technology in New Zealand

Orpyx Medical Technologies Inc. announced today that the New Zealand intellectual property office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx® product and future products, such as SurroGait Rx (TM), in New Zealand.

read more

Orpyx LogR™ to be used to investigate markers for cardiovascular disease

Orpyx Medical Technologies Inc. today announced a clinical trial agreement with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School in Boston, USA. The study will use the Orpyx LogR plantar pressure research system to measure gait and balance parameters in a variety of patients with cardiac and vascular disorders in an attempt to correlate global musculoskeletal changes (as represented by balance/foot pressure physiology) to discrete subsets of cardiovascular disease.

read more

Orpyx Welcomes New Director

Orpyx Medical Technologies Inc. announced today that David Taylor has joined its Board of Directors, effective immediately. Mr. Taylor is the President of Resman Holdings Ltd., an investment firm with a diverse portfolio of investments across industries. 

read more

Orpyx’s LogR Steps Up for Athletes

The LogR from Orpyx Medical Technologies Inc. (“Orpyx”) was featured on The Discovery Channel’s hit television series, Daily Planet. The LogR system is a mobile kit targeted for research-focused plantar pressure measurement – collecting data in real time, in the real world. Samuel Blades, PhD candidate from the University of Victoria’s Department of Exercise was approached by the television station to record a segment on his applied sports science research. As described in the segment, the progress made to date is nothing short of “revolutionary”.

read more

info@orpyx.com
1.855.996.7799

U.S. Patent No. 10,004,428 - June 2018
U.S. Patent No. 9,778,131 B2 - October 2017
U.S. Patent No. D740,950 S - October 2015
Australia Patent No. 2011320072 - May 2016
Japan Patent No. 6004444 - October 2016
New Zealand Patent No. 611197 - November 2015

Subscribe to our newsletter
* indicates required